HK1074797A1 - Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection - Google Patents
Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejectionInfo
- Publication number
- HK1074797A1 HK1074797A1 HK05107225.7A HK05107225A HK1074797A1 HK 1074797 A1 HK1074797 A1 HK 1074797A1 HK 05107225 A HK05107225 A HK 05107225A HK 1074797 A1 HK1074797 A1 HK 1074797A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- combination
- transplant rejection
- immunosuppressive agents
- formula
- diamide derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42832802P | 2002-11-21 | 2002-11-21 | |
PCT/US2003/037418 WO2004047826A1 (fr) | 2002-11-21 | 2003-11-21 | Combinaison de derives de diamide et agents immunosuppresseurs pour l'induction de la tolerance immunitaire |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1074797A1 true HK1074797A1 (en) | 2005-11-25 |
Family
ID=32393383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05107225.7A HK1074797A1 (en) | 2002-11-21 | 2005-08-19 | Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection |
Country Status (10)
Country | Link |
---|---|
US (3) | US7217718B2 (fr) |
EP (1) | EP1562571B1 (fr) |
JP (2) | JP4914008B2 (fr) |
AT (1) | ATE520400T1 (fr) |
AU (1) | AU2003291143A1 (fr) |
DK (1) | DK1562571T3 (fr) |
ES (1) | ES2371635T3 (fr) |
HK (1) | HK1074797A1 (fr) |
PT (1) | PT1562571E (fr) |
WO (1) | WO2004047826A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2408408C (fr) | 2000-05-12 | 2013-07-09 | Genzyme Corporation | Modulateurs de marquage du tnf-alpha |
PT1567138E (pt) * | 2002-11-21 | 2011-04-11 | Genzyme Corp | Utilização de derivados de diamida para inibição de rejeição crónica de transplante |
WO2004047826A1 (fr) * | 2002-11-21 | 2004-06-10 | Genzyme Corporation | Combinaison de derives de diamide et agents immunosuppresseurs pour l'induction de la tolerance immunitaire |
EP2827861A4 (fr) * | 2012-03-19 | 2016-03-16 | Aposignal Bioscience Llc | Composition et procédés pour une modulation cellulaire |
ITMI20120814A1 (it) * | 2012-05-11 | 2013-11-12 | Diego Dolcetta | Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB401747A (en) * | 1932-12-28 | 1933-11-23 | Charles Hepburn Myrtle | Method of and means for disinfecting air and distributing the treated air |
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US4944796A (en) * | 1988-11-14 | 1990-07-31 | Ici Americas Inc. | Certain 2-(disubstituted amino) acetanilide herbicides |
US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
US4997950A (en) * | 1989-04-20 | 1991-03-05 | Richard Finbar Murphy | Novel C-terminal gastrin antagonists |
US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
US5958413A (en) * | 1990-11-01 | 1999-09-28 | Celltech Limited | Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor |
US6420374B1 (en) * | 1990-11-30 | 2002-07-16 | Fred Hutchinson Cancer Research Center | Use of xanthines as immunosuppressants and to inhibit allograft reactions |
US5861382A (en) * | 1992-05-01 | 1999-01-19 | Yeda Research And Development Co. Ltd. | Methods for regulation of active TNF-α |
US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
CA2146647C (fr) | 1992-10-08 | 2009-05-05 | Marc Feldmann | Traitement d'affections auto-immunes et inflammatoires |
US6080407A (en) * | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
JPH09510952A (ja) | 1993-10-06 | 1997-11-04 | ザ ケネディー インスティチュート オブ リューマトロジー | 自己免疫疾患および炎症性疾患の治療 |
NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
DE4430128A1 (de) * | 1994-08-25 | 1996-02-29 | Hoechst Ag | Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen |
DE4430127A1 (de) * | 1994-08-25 | 1996-03-14 | Hoechst Ag | Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat |
US5932737A (en) * | 1994-12-02 | 1999-08-03 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds for treatment of no-mediated diseases |
US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
FR2730411B1 (fr) * | 1995-02-14 | 1997-03-28 | Centre Nat Rech Scient | Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes |
US5654312A (en) * | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
ATE259235T1 (de) * | 1995-07-20 | 2004-02-15 | Cell Eng Ag | Zubereitung enthaltend glykane übereinstimmend mit transferrin glykaner als aktives prinzip für die induktion der immuntoleranz gegen antigene |
IL115245A (en) * | 1995-09-11 | 2002-12-01 | Yissum Res Dev Co | Tumor necrosis factor inhibiting pharmaceuticals |
ATE215946T1 (de) * | 1995-11-22 | 2002-04-15 | Darwin Discovery Ltd | Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf) |
US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US6211160B1 (en) * | 1996-09-06 | 2001-04-03 | The Trustees Of The University Of Pennsylvania | Method for tolerizing a mammalian patient to administration of gene therapy virus vectors |
EP0942740B1 (fr) * | 1996-12-06 | 2003-08-27 | Amgen Inc., | Therapie combinatoire utilisant une proteine de liaison du facteur de necrose tumorale (tnf) dans le traitement de maladies induites par le tnf |
DE69837322T2 (de) * | 1997-01-10 | 2007-11-22 | Biogen Idec Ma Inc., Cambridge | Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln |
US6294170B1 (en) * | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
WO1998039026A2 (fr) * | 1997-03-07 | 1998-09-11 | Biogen, Inc. | Procedes d'administration therapeutiques de composes anti-cd40l |
US5801193A (en) * | 1997-04-15 | 1998-09-01 | Immune Modulation, Inc. | Compositions and methods for immunosuppressing |
US6506569B1 (en) * | 1997-05-30 | 2003-01-14 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR10 |
US6503184B1 (en) * | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
US6407218B1 (en) * | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
US6359061B1 (en) * | 1999-03-19 | 2002-03-19 | Isis Pharmaceuticals, Inc. | Amide compound libraries |
WO2000059874A1 (fr) * | 1999-04-02 | 2000-10-12 | Du Pont Pharmaceuticals Company | Nouveaux derives d'amides faisant office d'inhibiteurs de metalloproteases matricielles, de tnf-alpha, et de l'aggrecanase |
US6204245B1 (en) * | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
WO2001034649A2 (fr) * | 1999-11-09 | 2001-05-17 | Chiron Corporation | Compositions et methodes de traitement de maladies auto-immunes et des rejets de greffon |
CA2408408C (fr) * | 2000-05-12 | 2013-07-09 | Genzyme Corporation | Modulateurs de marquage du tnf-alpha |
WO2001090074A2 (fr) * | 2000-05-22 | 2001-11-29 | Leo Pharma A/S | Benzophenones comme inhibiteurs de l'il-1$g(b) et tnf-$g(a) |
WO2004003154A2 (fr) * | 2002-06-26 | 2004-01-08 | The Trustees Of Columbia Uninersity In The City Of New York | Utilisation de la streptavidine pour inhiber le rejet de transplantation |
PT1567138E (pt) * | 2002-11-21 | 2011-04-11 | Genzyme Corp | Utilização de derivados de diamida para inibição de rejeição crónica de transplante |
WO2004047826A1 (fr) * | 2002-11-21 | 2004-06-10 | Genzyme Corporation | Combinaison de derives de diamide et agents immunosuppresseurs pour l'induction de la tolerance immunitaire |
CA2653848A1 (fr) * | 2006-05-31 | 2007-12-06 | Genzyme Corporation | Procedes d'utilisation de globuline anti-thymocyte et agents associes |
-
2003
- 2003-11-21 WO PCT/US2003/037418 patent/WO2004047826A1/fr active Application Filing
- 2003-11-21 DK DK03783737.4T patent/DK1562571T3/da active
- 2003-11-21 PT PT03783737T patent/PT1562571E/pt unknown
- 2003-11-21 JP JP2004555618A patent/JP4914008B2/ja not_active Expired - Fee Related
- 2003-11-21 ES ES03783737T patent/ES2371635T3/es not_active Expired - Lifetime
- 2003-11-21 EP EP03783737A patent/EP1562571B1/fr not_active Expired - Lifetime
- 2003-11-21 AT AT03783737T patent/ATE520400T1/de active
- 2003-11-21 AU AU2003291143A patent/AU2003291143A1/en not_active Abandoned
- 2003-11-21 US US10/719,701 patent/US7217718B2/en not_active Expired - Lifetime
-
2005
- 2005-08-19 HK HK05107225.7A patent/HK1074797A1/xx not_active IP Right Cessation
-
2007
- 2007-03-06 US US11/714,692 patent/US7678822B2/en not_active Expired - Lifetime
-
2010
- 2010-01-21 US US12/691,266 patent/US20100233158A1/en not_active Abandoned
- 2010-10-21 JP JP2010236925A patent/JP2011016851A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ATE520400T1 (de) | 2011-09-15 |
JP2006514015A (ja) | 2006-04-27 |
JP2011016851A (ja) | 2011-01-27 |
US20100233158A1 (en) | 2010-09-16 |
WO2004047826A1 (fr) | 2004-06-10 |
PT1562571E (pt) | 2011-11-25 |
EP1562571A1 (fr) | 2005-08-17 |
ES2371635T3 (es) | 2012-01-05 |
DK1562571T3 (da) | 2011-12-05 |
US20070219264A1 (en) | 2007-09-20 |
US7678822B2 (en) | 2010-03-16 |
US7217718B2 (en) | 2007-05-15 |
AU2003291143A1 (en) | 2004-06-18 |
EP1562571B1 (fr) | 2011-08-17 |
US20040167202A1 (en) | 2004-08-26 |
JP4914008B2 (ja) | 2012-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL148903A0 (en) | Certain alkylene diamine-substituted heterocycles | |
YU3902A (sh) | Imidazoimidazoli i triazoli kao anti-inflamatorna sredstva | |
MY137250A (en) | Method of treatment of transplant rejection | |
MX2007004183A (es) | Derivados de benzoimidazol utiles como agentes antiproliferacion. | |
TW200642683A (en) | Heterocyclic compound | |
RS20090249A (en) | Spiroketone acetyl-coa carboxylase inhibotors | |
TW200621233A (en) | HCV NS3-NS4A protease inhibition | |
TW200718422A (en) | 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | |
HK1089973A1 (en) | Compounds for inflammation and immune-related uses | |
HK1074797A1 (en) | Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection | |
TW200510317A (en) | Caspase inhibitors and uses thereof | |
TNSN05197A1 (en) | Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation -and immunologically- mediated diseases | |
EP0815859A4 (fr) | Inhibiteurs d'epaississement de l'intima | |
NO20002589L (no) | Bifenylamidinderivater | |
WO2007014934A8 (fr) | Derives de quinoleine utilises comme agents antibacteriens | |
MXPA06002767A (es) | 2-carbonilamino-6-piperidinaminopiridinas substituidas y 1-carbonilamino-3-piperidinaminobenzenos y sustituidos como agonistas de 5-ht1f. | |
TNSN08546A1 (en) | Aminoalcohol derivative and immunosuppressive agent having same as an active ingredient | |
JO2752B1 (en) | Quinoline derivatives acting as antibacterial agents | |
MY151030A (en) | Quinoline derivatives as antibacterial agents | |
MXPA05011521A (es) | Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo. | |
EP1734046A4 (fr) | Radiosensibilisant | |
MXPA03011790A (es) | Agente para la procteccion de neuronas de la retina. | |
AU1076802A (en) | Selective glucocorticoid receptor agonists | |
TW200514553A (en) | Therapeutic agent for hepatitis C | |
WO2004007498A3 (fr) | Analogues de 3-phenyle de toxoflavine en tant qu'inhibiteurs de kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AM | Amended specification (according sect 146 of patent law) |
Free format text: CORRECTION OF THE NAME OF APPLICANT FROM GENZYEM CORPORATION TO GENZYME CORPORATION. |
|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20191121 |